At a glance
ClinicalIndex Comparison RecordN/ACompleted· 421 enrolled
Drug / intervention
Supartz +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Double-Blind, Parallel Controlled Non-Inferiority Clinical Trial Comparing 3 Weekly Intra-articular Injections of SUPARTZ® vs 3 Weekly Intra-articular Injections of Euflexxa® for Treatment of Knee OA
In Brief
A clinical study evaluating Supartz and Euflexxa for Osteoarthritis. Completed, enrolled 421 participants across 1 site.
Detailed Summary
The purpose of this study is to demonstrate non-inferiority of three weekly intra-articular injections of SUPARTZ to three weekly intra-articular injections of Euflexxa for the relief of knee OA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
CollaboratorsSeikagaku Corporation
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedApr 2014
Primary CompletionNov 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedApr 10, 2014
Enrollment StartMar 1, 2014
Primary CompletionNov 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.2 years ago
Interventions
Supartzdevice
Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
Euflexxadevice
Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.